23.09.2026
Canvax is expanding its rHSA offering to support biopharmaceutical manufacturing, cell and gene therapy, vaccines and advanced formulation workflows. This recombinant Human Serum Albumin provides an animal-origin-free alternative to plasma-derived human serum albumin (HSA), helping manufacturers reduce biological sourcing risks while maintaining high purity and batch-to-batch consistency.
Available as a 20% solution, recombinant albumin can be used as an excipient or ancillary material in applications where protein stabilization, reduced surface adsorption and formulation robustness are critical. Canvax offers material for research and development as well as GMP-grade recombinant human albumin for projects progressing towards regulated manufacturing.